Skip to main content

Table 2 Clinical characteristics of diabetic HFpEF patients according to glycemic control

From: Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort

  Diabetic N = 65 HbA1C < 7% N = 32 HbA1C > 7% N = 33 p-value
Age (years) 76 ± 9 76 ± 8 75 ± 10 0.79
Duration of diabetes (years) 19.3 ± 8 19.2 ± 9 19.4 ± 8 0.96
Female (n, %) 42 (60%) 20 (62%) 20 (61%) 0.88
Body mass index (kg/m2) 31 ± 6 29 ± 6 32 ± 7 0.048
NYHA III–IV (n, %) 27 (39%) 14 (44%) 12 (36%) 0.54
Hospitalized for HF at inclusion (n,%) 41 (63%) 21 (66%) 20 (61%) 0.55
Atrial fibrillation (n, %) 37 (53%) 18 (56%) 16 (48%) 0.53
Ischemic cardiomyopathy (n, %) 33 (47%) 13 (41%) 18 (55%) 0.26
Smoking (n, %) 27 (39%) 10 (31%) 14 (42%) 0.35
Hypertension (n, %) 67 (97%) 32 (100%) 31 (94%) 0.49
Hypercholesterolemia (n, %) 49 (70%) 22 (69%) 24 (73%) 0.72
Sleep apneas (n, %) 12 (18%) 4 (13%) 8 (27%) 0.16
COPD (n, %) 7 (10%) 3 (9%) 3 (9%) 0.97
Biology
 HbA1C (%) 7.1 [6.1–7.8] 6.1 [5.8–6.5] 7.7 [7.2–8.4]  < 0.001 by design
 eGFR (ml/min/1.73m2) 50 ± 24 49 ± 27 48 ± 18 0.78
 Hemoglobin (g/dL) 11 ± 2 11 ± 2 12 ± 2 0.046
 NT-proBNP (pg/mL) 1745 [955–3710] 2373 [1148–5264] 1464 [506–3696] 0.086
Antidiabetic treatment
 Insulin (n, %) 32 (46%) 11 (34%) 21 (64%) 0.018
 Metformin (n, %) 31 (44%) 15 (47%) 13 (39%) 0.54
 Sulfonylureas (n, %) 16 (23%) 9 (28%) 5 (15%) 0.20
 Gliptins (n, %) 8 (11%) 4 (13%) 4 (12%) 0.96
  1. Continuous variables are expressed as mean ± 1 standard deviation (SD) and categorical variables as count and proportion. p-values are derived from independent sample t-test or Chi square test when appropriate
  2. HbA1C: glycated hemoglobin; NYHA: New York Heart Association; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate estimated by CKD-epi